background: rh (rhesus) is a highly complex blood group system in man deeply rooted in transfusion medicine. isolation of rhd from cord blod, cloning and expression of recombinant rhd antigen in bacterial expression system was the aim of this study. methods: total rnas were extracted from cord blood (o + ).  the quality of rna was determined by electrophoresis. in or­der to obtain coding sequen...

background: the rh antigens are expressed as parts of a protein complex in the rbc membrane. this complex is a tetramer, consisting of two molecules of rhag and two molecules of rh proteins. to express rhd in rbc membrane, expression of rhag is essential. this co-expression only occurs in the erythroid lineage. k562 cell line has an erythroid lineage. materials and methods: cord blood was used ...

Background: The Rh antigens are expressed as parts of a protein complex in the RBC membrane. This complex is a tetramer, consisting of two molecules of RhAG and two molecules of Rh proteins. To express RhD in RBC membrane, expression of RhAG is essential. This co-expression only occurs in the erythroid lineage. K562 cell line has an erythroid lineage. Materials and Methods: Cord blood was used ...

In this issue of Blood, Robak et al present data suggesting that rozrolimupab, a firstin-class mixture of 25 recombinant monoclonal IgG1 antibodies against RhD, has efficacy similar to plasma-derived anti-RhD in the treatment of immune thrombocytopenia.1 P lasma-derived anti-RhD, a hyperimmune preparation of IgG that targets the RhD antigen on erythrocytes, is a standard first-line therapy in n...

A single recombinant immunoglobulin G1 (IgG1) anti-RhD antibody (MonoRho) was compared with a currently used polyclonal anti-RhD product (Rhophylac) in a phase 1 study for safety, efficacy of Rhesus D (RhD)–positive red blood cell (RBC) clearance, and prevention of RhD immunization in RhD-negative men challenged with 15 mL RhD-positive RBCs. Both the polyclonal product and recombinant antiRhD e...

Ciljana zaščita z imunoglobulinom anti-D je program, ki na podlagi presejalnega testa omogoča neinvazivno določitev plodovega genotipa RHD iz periferne krvi RhD-negativne nosečnice. Pred uvedbo določanja predvidenega fenotipa RhD so vse nosečnice prejele zaščito v 28.–30. tednu nosečnosti. V Evropi 40 % RhD-negativnih nosečnic nosi RhD-negativen plod in zaščite ne potrebuje, saj med materjo plo...

A single recombinant immunoglobulin G1 (IgG1) anti-RhD antibody (MonoRho) was compared with a currently used polyclonal anti-RhD product (Rhophylac) in a phase 1 study for safety, efficacy of Rhesus D (RhD)-positive red blood cell (RBC) clearance, and prevention of RhD immunization in RhD-negative men challenged with 15 mL RhD-positive RBCs. Both the polyclonal product and recombinant anti-RhD ...

A single recombinant immunoglobulin G1 (IgG1) anti-RhD antibody (MonoRho) was compared with a currently used polyclonal anti-RhD product (Rhophylac) in a phase 1 study for safety, efficacy of Rhesus D (RhD)–positive red blood cell (RBC) clearance, and prevention of RhD immunization in RhD-negative men challenged with 15 mL RhD-positive RBCs. Both the polyclonal product and recombinant antiRhD e...